Explore how genetic testing and precision oncology are revolutionizing cancer treatment by offering personalized care and ...

Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but ... noninvasive alternative to ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

While circulating tumor cells (CTCs) are better suited for personalized therapy and prognosis, cell-free DNA (cfDNA) and extracellular vesicle-based technologies show potential for early diagnosis, ...

Alongside PSA genomic markers, mutations in the BRCA1 and BRCA2 genes have become increasingly important. These mutations, detected via germline, somatic tumor testing, or increasingly through liquid ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform ... decisions.” The tissue-free Guardant Reveal test uses a blood sample, in contrast to tumor-informed approaches ...

The latest buzz in the cancer diagnosis and treatment arena is a revolutionary technology called liquid biopsy. Unlike tissue biopsies ... uses these fragments to test cancer and assess its ...

A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published today, Feb. 12, in ...